drugset / Trial / NCT00841191
A Safety, Efficacy and Pharmacokinetic Study of Siltuximab (CNTO 328) in Participants With Solid Tumors
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the recommended dose of siltuximab monotherapy, in participants with solid malignant (cancerous) tumors (a mass in a specific area) and to estimate the clinical benefit of siltuximab monotherapy in participants with ovarian cancer and with Kirsten rat sarcoma viral oncogene homolog (KRAS) mutant tumors.
Timeline
- Start
- 2009-03
- Primary completion
- 2011-04
- Completion
- 2011-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Siltuximab | Monoclonal antibody | 2.8 mg/kg | Intravenous |
| Subject | Siltuximab | Monoclonal antibody | 5.5 mg/kg | Intravenous |
| Subject | Siltuximab | Monoclonal antibody | 11 mg/kg | Intravenous |
| Subject | Siltuximab | Monoclonal antibody | 15 mg/kg | Intravenous |